AstraZeneca Plc. reported significantly higher profit in the third quarter, with core earnings and revenues exceeding market estimates. The firm maintained a positive outlook for fiscal 2025, with expectations of low double-digit growth in core earnings per share and high single-digit growth in total revenue. In the third quarter, profit before tax surged 77% to $3.24 billion, while total revenue increased by 12% to $15.19 billion. Earnings per share were $1.62, higher than the previous year. Core earnings per share were $2.38, beating Wall Street analysts’ expectations.

Read more at Nasdaq: AstraZeneca Q3 Results Climb, Top Estimate; Backs FY25 Outlook